10x Genomics has acquired Scale Biosciences, gaining key inventions and technologies and broadening access to single cell analysis. 

Scale Biosciences was founded by a multidisciplinary team of scientists and technologists with expertise in next generation sequencing, genomics, and bioinformatics: Professor Garry Nolan at Stanford University, Professors Jay Shendure and Cole Trapnell at University of Washington and Frank Steemers. 

Their work in combinatorial indexing and quantum barcoding represents a key advancement in scalable single cell analysis. 

“At 10x, we’re relentlessly innovating to build a world where single cell analysis is routine, accessible, and scalable at levels previously unimaginable,” said Serge Saxonov, CEO of 10x Genomics. “This acquisition is a step towards that vision – reflecting our commitment to accelerating adoption of single cell technologies. By integrating Scale’s inventions with 10x’s global platform and innovation engine, we will broaden the capabilities and reach of existing and future products.”  

10x Genomics says the acquisition is part of an ambitious multi-year product roadmap for single cell innovation.  

“These inventions were designed to make single cell analysis dramatically more scalable and accessible,” said Garry Nolan, Co-founder of Scale Biosciences and Professor at Stanford University. “They have already advanced biological discovery, and with 10x’s innovation engine, that impact will only accelerate. This integration will help the research community generate the high-quality data needed to drive AI-powered breakthroughs in medicine.” 

10x will support current Scale customers with ongoing experiments, as well as initiatives such as the 100 Million Cell Challenge and the Billion Cells Project. In addition, key Scale products will remain on the market.

DIANA TURNER, Senior Digital Content Editor, DDW